Letter to the editor raises questions about fluvoxamine study in ICU patients

Key Messages

The writer acknowledges that fluvoxamine has shown benefits in mild COVID-19 patients, and has plausibile anti-COVID mechanisms.

The author raises questions about the design of the study of fluvoxamine in COVID-19 patients by Dr. Calusic and colleagues, which showed that fluvoxamine lowers death rate by 40%, and suggests possible bias in the study design and analysis.

British Journal of Clinical Pharmacology

Publication Date: February 7, 2022
Peer Reviewed: Yes
Publication Type: Review/Commentary/Letter
DOI: https://www.doi.org/10.1111/bcp.15166

Fluvoxamine for COVID-19 ICU patients?

Vladimir Trkulja

Abstract

No abstract available